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Abstract
Purpose—Hsp90 is important in the folding, maturation and stabilization of pro-tumorigenic
client proteins and represents a viable drug target for the design of chemotherapies. Previously, we
reported the development of novobiocin analogues designed to inhibit the C-terminal portion of
Hsp90, which demonstrated the ability to decrease client protein expression. We now report the
characterization of the novel novobiocin analogue, F-4, which demonstrates improved cytotoxicity
in prostate cancer cell lines compared to the N-terminal inhibitor, 17-AAG.
Materials and Methods—LNCaP and PC-3 cells were treated with 17-AAG or F-4 in anti-
proliferative, apoptosis, cell cycle and cytotoxicity assays. Western blot and prostate specific
antigen (PSA) ELISAs were used to determine client protein degradation, induction of Hsp90 and
to assess the functional status of the androgen receptor (AR) in response to F-4 treatment. Surface
Plasmon Resonance (SPR) was also used to determine the binding properties of F-4 to Hsp90.
Results—F-4 demonstrated improved potency and efficacy compared to novobiocin in anti-
proliferative assays and decreased expression of client proteins. PSA secretion was inhibited in a
dose-dependent manner that paralleled a decrease in AR expression. The binding of F-4 to Hsp90
was determined to be saturable with a binding affinity (Kd) of 100 µM. In addition, superior
efficacy was demonstrated by F-4 compared to 17-AAG in experiments measuring cytotoxicity
and apoptosis
Conclusions—These data reveal distinct modes of action for N-terminal and C-terminal Hsp90
inhibitors, which may offer unique therapeutic benefits for the treatment of prostate cancer.
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Prostate cancer remains a significant health problem in the United States, responsible for
30,000 deaths annually, and is the second leading cancer killer of men (1). Patients with
metastatic, locally recurrent, and androgen-independent prostate cancer are particularly
problematic. Although recent trials demonstrate a modest survival advantage for docetaxel,
the effectiveness of chemotherapy remains limited in these cases (2,3). Since prostate cancer
is a heterogeneous disease with multiple contributing pathways, one strategy in the design of
novel therapies is a focus on single agents with the ability to target multiple pathways.
Heat shock protein 90 (Hsp90) is a molecular chaperone responsible for folding nascent
polypeptides into their biologically active conformations. In cancer, Hsp90 facilitates the
conformational maturation of dormant oncogenic proteins important to tumorigenesis and
cancer cell survival (4,5). Additionally, tumor cells exhibit higher Hsp90 activity and
increased accumulation of Hsp90 inhibitors compared to normal cells, which may allow for
the design of tumor-selective inhibitors (6,7). In contrast to traditional cancer therapeutics
directed against one molecular target, disruption of the Hsp90 machinery may
simultaneously inhibit multiple therapeutic targets and pathways critical to tumor survival.
Thus, Hsp90 inhibitors represent an exciting new strategy in the development of prostate
chemotherapies.
Traditionally, Hsp90 inhibitors have targeted the N-terminal ATP-binding site. Previous
studies utilizing N-terminal inhibitors have demonstrated activity of these compounds in
vitro and in vivo, and clinical trials are ongoing. Unfortunately, their use has been hampered
by significant toxicity and problematic pharmacodynamic properties (8). More recently, a
second ATP-binding site was identified in the carboxyl terminus of Hsp90 (9). Inhibition of
the Hsp90 C-terminal ATP binding site decreases chaperone dimerization, diminishes
ATPase activity and impairs formation of the Hsp90-client protein complex, resulting in
improperly folded proteins that are targeted for the ubiquitin-proteasomal degradation
pathway (10). The coumarin antibiotic novobiocin (NB) has been demonstrated to bind to
the C-terminal ATP site of Hsp90 (11,12). Clinically, NB has been used for its antimicrobial
activity with acceptable toxicity and bioavailability. Unfortunately, it exhibits a low affinity
for Hsp90 with an IC50 of ~400 µM and would require high concentrations for maximal
effects (11,12). Thus, we hypothesized that NB analogues with improved affinity for Hsp90
may represent effective therapy for prostate cancer. We have recently reported the synthesis
and screening of NB analogues designed to bind to the Hsp90 C-terminal domain (11,13).
Herein, we report the characterization of a novel analogue, F-4, in prostate cancer cell lines.
MATERIALS AND METHODS
Materials
NB analogues were synthesized as previously described (14). F-4 was dissolved in DMSO
and stored at −20°C until use. Commercial antibodies were obtained for the androgen
receptor (AR) (Cell Signaling Technologies, Danvers, MA), AKT, Hsp90, HER-2, and
Actin (Santa Cruz Biotechnology Inc., Santa Cruz, CA), HIF-1α (Novus Biologicals,
Littleton, CO), Hsp70 and GAPDH (Cell Signaling Technologies, Danvers, MA).
Cell culture
LNCaP (androgen-dependent) and PC-3 (androgen-independent) prostate cancer cell lines
were obtained from American Type Culture Collection (Manassas, VA) and cultured in
RPMI 1640 and Ham’s F-12 media, respectively, with 10% FBS and penicillin/
streptomycin (100 IU/ml/ 100ug/ml) and maintained at 37°C with 5% CO2.
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The CellTiter 96 AQueous One Solution Cell Proliferation Reagent (Promega) was used
according to manufacturer protocol as previously described (15). Briefly, cell proliferation
was measured by bioreduction of a tetrazolium (MTS) dye to a formazan by-product, which
corresponds directly to viable cell number. Cells were incubated for 48 hours then treated
for the indicated timepoints. Plates were analyzed on the VICTOR3V Multilabel Reader
(PerkinElmer) at 490 nm. Data was analyzed from 2–4 independent experiments performed
in duplicate then normalized to absorbance of wells containing media only (0%) and
untreated cells (100%). Non-linear regression and sigmoidal dose-response curves
(GraphPad Prism) were used to calculate IC50, IC90, and R2 values.
Trypan Blue cytotoxicity experiments
Cells were treated for the indicated timepoints then floating and adherent cells were
collected. Each sample was mixed with equal parts Trypan Blue and analyzed on the VI-
CELL Series Cell Viability Analyzer (Beckman Coulter, Fullerton, CA). Percentage of
viable cells was calculated by determining the ratio of Trypan Blue-positive to negative
cells.
Western Blot analysis
Western blot analysis was performed as previously described (16). Briefly, cells were
treated with F-4 or vehicle (DMSO) for indicated times. Lysates were prepared, and equal
amounts of protein were electrophoresed under reducing conditions on 4–12% Tris-Glycine
gels (Invitrogen, Carlsbad, CA), transferred to a PVDF membrane (Millipore, Bedford, MA)
then blocked in TBS-T containing 5% milk and probed with primary antibodies. Membranes
were incubated with a horseradish peroxidase-conjugated secondary antibody, developed
with chemiluminescence substrate (Pierce Biotechnology, Rockford, IL), and visualized
with the UVP AutoChemi system (UVP, LLC, Upland, CA). All Western blots were probed
for loading controls Actin or GAPDH. The data were representative of at least three
independent experiments (n=3).
PSA ELISA assay
In vitro measurement of prostate specific antigen (PSA) secretion from LNCaP cells was
assessed using the BioQuant PSA ELISA kit (BioQuant, Nashville, TN) according to
manufacturer’s instructions. Cells were cultured in medium containing 2% charcoal dextran-
stripped serum for 3 days to reduce hormones to basal levels then treated with F-4 for 24
hours. Cells were either incubated with F-4 alone or in the presence of 100 nM testosterone
(TST) for an additional 24 hours. Following incubation, samples of LNCaP-conditioned
media were analyzed for PSA. Data was analyzed as described under Anti-Proliferative
Assay. Data points represented the mean ± SEM of duplicate wells from four independent
experiments (n=4).
Annexin V apoptosis experiments
Annexin V-FITC and propidium iodide (PI) (Anaspec, San Jose, CA) were prepared
according to the manufacturer’s instructions. Cells were treated, floating and adherent cells
were collected, and the resulting cell suspension was washed in Annexin Binding Buffer
(ABB) (150 µM NaCl, 5 µM KCl, 1 µM MgCl2·6H20, 1.8 µM CaCl2·2H20, 10 mM HEPES,
and 2% FBS). Half the cell suspension was used for Cell Cycle Analysis (see below). The
remaining cell suspension was stained with Annexin V-FITC (BD Pharmingen, San Jose,
CA) and propidium iodide (Sigma Aldrich, St. Louis, MO) then washed and fixed in
paraformaldehyde. Samples were analyzed using the BD LSRII System (BD Biosciences,
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San Jose, CA) and were gated identically for all experiments. The data displayed represented
the mean ± SEM of three independent experiments (n=3).
Cell cycle analysis
Cells were centrifuged and resuspended in 0.9% NaCl followed by drop-wise addition of
90% EtOH to fix cells. Samples were centrifuged then resuspended in PI followed by
incubation with 1 mg/mL RNase A (Sigma Aldrich, St. Louis, MO). Samples were analyzed
as described under Annexin V methods.
Statistical analysis
Data from Annexin V apoptosis, cell cycle, and Trypan Blue experiments were analyzed
using a two-tailed t-test (GraphPad Prism 5.0, La Jolla, CA). All data displayed represented
the mean ± SEM of at least three independent experiments (n=3).
Surface Plasmon Resonance (SPR) Analysis
Insect Sf9 cells overexpressing Hsp90β were cultured and harvested by the Baculovirus/
Monoclonal Antibody Core facility at Baylor College of Medicine. Hsp90β was extracted
and purified (>98% pure) as described previously(17,18), but without the initial DEAE-
cellulose chromatography step. The surface of a SSOO COOH1 SPR sensor chip mounted in
a SensiQ SPR instrument (ICX Nomadics) was activated by treatment with N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide for
preferential cross-linking of the protein’s N-terminus to the surface. For Hsp90
immobilization, 250 µL of Hsp90 (7 mg/ml) in 20 mM sodium bicarbonate buffer (pH 8)
containing 150 mM NaCl was injected at a flow rate of 10 µL/min, giving 2800 response
units of protein stably immobilized to surface of the flowcell, representing ~0.08 picomoles
of Hsp90. Unreactive groups were then quenched with 1 M ethanolamine (pH 8), and the
surface washed with buffer containing 10 mM PIPES pH 7.4, 300 mM NaCl, and 2%
DMSO. F-4 was diluted in assay buffer containing 10 mM PIPES pH 7.4, 300 mM NaCl,
and 2% DMSO and injected over the surface of the derivatized chip at a flow rate of 25 µL/
min at 25°C at the indicated concentrations. All measurements were done in triplicate. SPR
binding curves were analyzed using QDAT software (ICX Nomadics) to calculate the Kd
and re-graphed using Origin software for Scatchard analysis and to demonstrate saturation
of binding.
RESULTS
Anti-proliferative effects of F-4 in prostate cancer cell lines
The anti-proliferative effects of F-4, 17-AAG, and NB were examined over a 72 hour time-
course in LNCaP and PC-3 cells (Figure 1). At all timepoints, F-4 dose-response curves
were nearly superimposable with marginal improvement over time indicating that maximal
efficacy (IC90) and potency (IC50) was essentially achieved at 24 hours (Table 1).
Conversely, 17-AAG required at least 48–72 hours treatment to achieve superior efficacy
and potency in both cell lines. F-4 was 14–24 fold and 7–9 fold more potent (IC50)
compared to the parent compound NB in the LNCaP and PC-3 cell lines, respectively, at all
timepoints. These findings suggested that the NB analogue, F-4, required less time to exert
its anti-proliferative effects compared to 17-AAG, which required 48–72 hours of
continuous exposure to elicit maximal response.
Cytotoxicity of F-4 in prostate cancer cells
Since the previous assays in Figure 1 measure proliferation and not cytotoxicity, prostate
cancer cells were examined to discern the relationship between anti-proliferative activity and
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cytotoxicity. LNCaP (Figure 2, top panels) and PC-3 (Figure 2, bottom panels) cells were
treated for 24 (panels A & D), 48 (panels B & E), or 72 (panels D & F) hours, and cell death
was measured using the Trypan Blue exclusion assay. A dose-dependent increase in cell
death was observed at concentrations of F-4 ranging from 25–50 µM and 50–100 µM in
LNCaP and PC-3 cells, respectively. Additionally, 17-AAG was examined at concentrations
ranging from 1–100 µM (highest dose shown) and only demonstrated appreciable
cytotoxicity at the 100 µM dose following 72 hours treatment. Thus, these data demonstrate
a strong correlation of the anti-proliferative effect of F-4 with its cytotoxic effects, whereas
the potent anti-proliferative effect of 17-AAG reflects the cytostatic mechanism of the drug.
F-4 mediated degradation of client proteins
Client protein expression and subsequent degradation was examined in the LNCaP cell line
treated with F-4 for 24 hours. Degradation of the HSP90 client proteins, AR, HER-2 and
AKT, was observed in a dose-dependent manner (Figure 3A). HIF-1α protein levels were
unaffected and the induction of Hsp90, a hallmark of HSP90 inhibition, was absent in F-4-
treated LNCaP cells. The loading control Actin was marginally affected at the highest
concentration.
In the PC-3 cell line, F-4 demonstrated degradation of the AKT and HER-2 proteins (Figure
3B) while Hsp90 expression was moderately increased following treatment with F-4 for 72
hours. HIF-1α levels appeared to be more sensitive to F-4-mediated client protein
degradation, for which decreased expression was observed following 24 hours of treatment.
These data demonstrate that F-4 triggers the degradation of client proteins, which is another
hallmark of Hsp90 inhibition.
F-4 diminishes androgen-induced PSA secretion
PSA expression and secretion is regulated by androgens binding to their cognate androgen
receptor (AR). Since F-4 decreases AR expression between 1–10 µM (Figure 3A), we
examined the corresponding effect of F-4 on the secretion of PSA in the androgen-
dependent LNCaP cells. Figure 4 demonstrates that treatment of LNCaP cells with
testosterone alone results in a robust increase in PSA that was abrogated with pre-treatment
of F-4. Furthermore, this was accomplished using drug concentrations previously shown to
manifest the degradation of AR (see Figure 3). These data demonstrated that PSA levels can
be utilized as a biomarker for assessing the effectiveness of C-terminal Hsp90 inhibitors in
androgen-dependent prostate cancer.
F-4 manifests induction of apoptosis in prostate cancer cells
Induction of apoptosis was determined by Annexin V binding to externalized
phosphatidylserine on the plasma membrane, and cell death was measured by propidium
iodide staining. Treatment of prostate cancer cells with F-4 for 72 hours resulted in a
dramatic dose-dependent induction of Annexin V staining compared to control (Figure 5A
& 5C). Interestingly, the LNCaP cell line (panel 5A) appeared to undergo early-stage
(quadrant IV) and late-stage (quadrant II) apoptosis that increased with dose while the less
sensitive PC-3 cell line (panel 5C) was only observed to undergo early apoptosis (quadrant
IV). Statistical analysis revealed a significant increase in total Annexin V staining at the 50
(p<0.05) and 100 µM (p<0.01) F-4 concentrations as compared to vehicle control (Figure
5B & 5D, respectively). Additionally, treatment of cells with a range of concentrations of
17-AAG (1–100 µM; highest dose shown) for 72 hours did not induce any appreciable
Annexin V staining. These findings demonstrated F-4 to be more effective at inducing
apoptosis in prostate cancer cells compared to 17-AAG.
Shawna et al. Page 5













Cell cycle effects of F-4 in prostate cancer cells
Cell cycle arrest, as determined by propidium iodide staining, was assessed in both prostate
cancer cell lines following F-4 treatment. LNCaP cells revealed a marked increase in the
sub-G0 percentage of cells (p<0.01) (Figure 6A) with a decrease in the percentage of cells in
the G0/G1 (p<0.05) and G2/M phase (p<0.05) (Figure 6B). The sub-G0 peak represented
cells undergoing apoptosis, characterized by the fragmentation and reduction in the amount
of cellular DNA. Conversely, cell cycle analysis of PC-3 cells following exposure to F-4
resulted in a dose-dependent G2/M arrest (p<0.05) (Figure 6C) with a corresponding
decrease in the percentage of cells in the G0/G1 phase of the cell cycle (p<0.05) (Figure
6D). Interestingly, treatment of both cell lines with a range of 17-AAG (1–100 µM; highest
dose shown) resulted mainly in a G2/M arrest at all concentrations with mild induction of
sub-G0 phase in only the LNCaP cell line at the highest concentration (Figure 6B & 6D).
These data reveal F-4 to be a more potent inducer of G2/M arrest and apoptosis in PC-3 and
LNCaP cell lines, respectively, compared to the N-terminal inhibitor 17-AAG.
Surface Plasmon Resonance (SPR) Analysis of F-4 Binding Hsp90
To demonstrate that Hsp90 specifically binds F-4, the interaction of F-4 with immobilized
Hsp90 was measured by surface plasmon resonance (SPR) spectroscopy. Figure 7 (panel A)
shows representative curves for the binding of F-4 to Hsp90. The binding of F-4 to Hsp90
was observed to be saturable (panel B) with a calculated Kd of 100 ± 10 µM and a
stoichiometry of two moles per mole of Hsp90 chain. The plot of bound F-4 versus F-4
concentration gave a sigmoidal-like curve suggestive of cooperative binding. The Scatchard
plot again suggested either cooperative binding of F-4 to Hsp90 or the presence of two
binding sites with different affinities. A Hill plot of the data (panel C) yielded an IC50 for
binding of 100 µM with a Hill coefficient of approximately two.
DISCUSSION
Hsp90 is a molecular chaperone required for the folding of nascent and denatured proteins.
In the absence or inactivation of Hsp90, these client proteins are targeted for ubiquitination
and proteasomal degradation. Though several N-terminal Hsp90 inhibitors have
demonstrated client protein degradation, many of these agents have been hampered in
clinical trials by high toxicity and poor solubility (19). The C-terminal ATP binding domain
of Hsp90 is important for dimerization and can be inhibited by NB. We hypothesized that
the targeting of Hsp90 by NB analogues would demonstrate a distinct mode of action
compared to N-terminal inhibitors.
In this study we have demonstrated the effectiveness of a novel NB analogue, F-4, in
comparison to 17-AAG. In anti-proliferation assays, F-4 demonstrates superior efficacy
(IC90) at 24 hours exposure compared to 17-AAG which requires 48–72 hours to achieve
maximal response. A hallmark of Hsp90 inhibition is the degradation of client proteins; we
therefore investigated the expression of client proteins previously established to be
important in prostate cancer (20–22).
F-4 treatment of prostate cancer cells demonstrated that some client proteins such as HER-2
and AKT were affected across cell lines but another client, HIF-1α, was only affected in the
PC-3 cell line. These data suggest that not all client proteins will be equally degraded
following Hsp90 inhibition across prostate cancers. Interestingly, the induction of Hsp90, a
hallmark of Hsp90 inhibition, is observed slightly in the PC-3 cell line and not at all in
LNCaP cells. To date, it is unclear how Hsp90 induction will affect the clinical outcomes of
N-terminal Hsp90 inhibitors. However, if this is proven to be undesirable, NB analogues
targeting the C-terminal end of Hsp90 may offer distinct advantages in that they limit the
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induction of Hsp90. Correspondingly, PSA levels decline at F-4 concentrations (10 µM) less
than that required for cytotoxicity (25–100 µM), indicating that the reduction in PSA is a
result of AR degradation and not cell death.
In studies examining cell cycle, induction of apoptosis and cytotoxicity of F-4 and 17-AAG,
we note several key observations. First, F-4 appeared to have distinct effects on cell cycle
causing LNCaP cells to shift into the sub-G0 apoptotic fraction and PC-3 cells to arrest in
G2/M phase. Second, the LNCaP cell line is approximately two fold more sensitive to F-4
with respect to the induction of apoptosis and cytotoxicity compared to PC-3 cells. These
observations, combined with the observed effects of F-4 on client proteins, suggest NB
analogues may exert cell type-specific modes of action. Lastly, 17-AAG treatment of
prostate cancer cells at concentrations up to 100 µM appeared to be largely cytostatic
causing a G2/M arrest with mild induction of apoptosis in the LNCaP cell line and
appreciable cytotoxicity seen only after 72 hours treatment.
Analysis of the binding of F-4 to Hsp90 by SPR indicated that Hsp90 binds F-4 specifically
and cooperatively with a Kd of 100 µM, a binding affinity that is comparable to that
previously reported for another novobiocin analogue, chlorobiocin (12). The Hill coefficient
for the binding of F-4 to Hsp90 was approximately two, indicating that the binding was
highly cooperative. The Hill coefficient is similar to that calculated for the binding of
novobiocin to Hsp90, which is estimated from the concentration-dependent changes in
Hsp90 conformation induced upon binding of Hsp90 to novobiocin (23).
CONCLUSIONS
The novobiocin analogue, F-4, is a putative C-terminal Hsp90 inhibitor with distinct
pharmacodynamics compared to the N-terminal inhibitor 17-AAG. At equal concentrations,
F-4 was demonstrated to be superior to 17-AAG at inducing apoptosis and causing
cytotoxicity, and may offer distinct advantages over N-terminal inhibitors in the treatment of
prostate cancer.
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Figure One. Anti-proliferative effects of F-4 in prostate cancer cell lines
LNCaP (top panels A–C) and PC-3 cells (bottom panels D–F) were treated with F-4, 17-
AAG, or novobiocin for 24(▼), 48(♦) and 72(●) hours. Bioreduction of tetrazolium (MTS)
dye to a formazan by-product was used to measure cellular proliferation. Combined
normalized data from independent experiments is shown for cells treated with F-4 (panels A
and D), 17-AAG (panels B and E), and novobiocin (panels C and F). Data was analyzed
from 2–4 independent experiments performed in duplicate; each data point represents the
mean ± SEM.
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Figure Two. Cytotoxicity of F-4 in prostate cancer cells
LNCaP and PC-3 cells were treated with F-4 for 24, 48, and 72 hours. Samples were mixed
with equal parts Trypan Blue and assessed for viability. Percentage viability was calculated
as described in Materials and Methods. Asterisk(s) *, **, *** indicates significant P value
<0.05, <0.01, and <0.001, respectively, by two-tailed t-test compared to vehicle-treated
control.
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Figure Three. F-4 mediated degradation of client proteins
LNCaP (panel A) and PC-3 (panel B) cells were treated with F-4 then examined by Western
blot for the degradation of client proteins. Actin (LNCaP) or GAPDH (PC-3) were used as
loading controls for each panel.
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Figure Four. F-4 diminishes androgen induced PSA secretion
LNCaP cells were grown in hormone-free media for 72 hours, pre-treated with F-4 for 24
hours then were incubated either with F-4(▲), 100 nM testosterone (TST) (●), or in
combination with F-4 (□). Data was analyzed from 4 independent experiments performed in
duplicate; each data point represents the mean ± SEM for values obtained in the PSA ELISA
assay.
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Figure Five. F-4 manifests induction of apoptosis in prostate cancer cells
LNCaP and PC-3 cells were treated with F-4 or 17-AAG for 72h. Representative flow
cytometry scatterplots depict percent Annexin V staining for LNCaP (panel A) and PC-3
cells (panel C) after F-4 and 17-AAG treatment. The four quadrants of the scatterplot
represent the percent of the parent population and indicate the following: I. PI- staining only
indicating necrosis; II. Annexin V and PI staining depicting late-stage apoptosis; III.
Negative staining indicating live cells; IV. Annexin V staining alone indicating early-stage
apoptosis. A bar graph depicting the total percent apoptosis (Annexin V positive cells in
quadrants II + IV) following treatment with statistical analysis is shown for LNCaP and
PC-3 cells (panels B and D, respectively). Asterisk(s) *, ** indicates significant P value
<0.05, and <0.01, respectively, by two-tailed t-test compared to vehicle-treated control.
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Figure Six. Cell cycle effects of F-4 in prostate cancer cells
Representative histograms are shown depicting the distribution of cell cycle as assessed by
PI staining following treatment of LNCaP (panel A) and PC-3 (panel C) cells with F-4 or
17-AAG for 72h. Bar graphs depicting the cell cycle distribution after treatment from three
independent experiments are shown with statistical analysis for LNCaP and PC-3 (panels B
and D, respectively). Asterisk(s) *, ** indicates significant P value <0.05 and <0.01,
respectively, by two-tailed t-test compared to vehicle-treated control.
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Figure Seven. Surface Plasmon Resonance (SPR) Analysis of F-4 Binding Hsp90
SPR analysis of the binding of F-4 to Hsp90 was carried out as described under Materials
and Methods. Panel A demonstrates representative binding curves of F-4 injected at the
indicated concentrations, while panel B displays replot of relative units at steady state
(RUsteadystate: amount bound) versus concentration of F-4. Panel C displays a Hill plot of the
binding of F-4 to Hsp90.
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